newsAnalysis reports nitrosamine prevalence in small molecule drugs5 June 2023 | By Catherine Eckford (European Pharmaceutical Review)Data from a paper on small molecule drugs has indicated nitrosamines in pharmaceuticals is likely more prevalent than originally expected.
newsNivolumab plus chemo provides one-year PFS in 94 percent lymphoma patients5 June 2023 | By Catherine Eckford (European Pharmaceutical Review)A PD-1 checkpoint inhibitor plus chemotherapy is expected to become new standard of care for advanced Hodgkin lymphoma, based on Phase III trial data.
newsNovel PAT system could enable adaptive process control2 June 2023 | By Catherine Eckford (European Pharmaceutical Review)A paper has demonstrated a novel refractometry-based process analytical technology (PAT) system has potential for enabling adaptive process control in CGT manufacturing.
newsNICE recommends oral migraine treatment for first time1 June 2023 | By Catherine Eckford (European Pharmaceutical Review)An oral small molecule CGRP antagonist has been recommended for episodic migraines in National Institute for Health and Care Excellence (NICE) final draft guidance.
newsMicrofluidic device detects bacteria concentration from small sample volumes1 June 2023 | By Catherine Eckford (European Pharmaceutical Review)A novel ultrasonic nanosieve enabled concentration of bacteria into a 1µL highly concentrated solution suitable for plate counting and PCR, according to research.
newsBig Pharma inventory management trends revealed31 May 2023 | By Catherine Eckford (European Pharmaceutical Review)Rapid growth of Big Pharma manufacturer inventories fail to prevent medicine shortages, a 2022 report has highlighted.
newsEuropean Commission approves haematology biosimilar30 May 2023 | By Catherine Eckford (European Pharmaceutical Review)A marketing authorisation for a biosimilar to eculizumab has been granted by the European Commission for paroxysmal nocturnal haemoglobinuria.
newsCHMP meeting highlights – May 202329 May 2023 | By Catherine Eckford (European Pharmaceutical Review)The Committee for Medicinal Products for Human Use (CHMP) recommended two new medicines for approval in its May meeting, including a neurosteroid for epileptic seizures.
newsNanoparticle HIV vaccine shows potential in trial25 May 2023 | By Catherine Eckford (European Pharmaceutical Review)Positive first-in-human trial results have highlighted potential of a nanoparticle vaccine towards broadly neutralising against HIV.
newsBenefits of blockchain in limiting counterfeit drug distribution22 May 2023 | By Catherine Eckford (European Pharmaceutical Review)Smart contracts on blockchain could help prevent distribution of counterfeit drugs in the pharmaceutical supply chain, a review shows.
newsFirst NICE-recommended treatment for chronic heart failure19 May 2023 | By Catherine Eckford (European Pharmaceutical Review)In final draft guidance, the National Institute for Health and Care Excellence (NICE) has recommended dapagliflozin (Forxiga) for patients with heart failure regardless of ejection fraction.
newsDigitalisation to boost quality management systems market17 May 2023 | By Catherine Eckford (European Pharmaceutical Review)Pharma has been implementing process digitalisation and automated quality management systems to improve efficiency in drug manufacturing, a report says.
newsRWE shows efficacy of nirsevimab for infant RSV15 May 2023 | By Catherine Eckford (European Pharmaceutical Review)New real-world data “adds to the evidence that use of long-acting monoclonal antibody [nirsevimab] may prevent moderate to severe respiratory syncytial virus disease” in infants after single dose.
articleRealising milestones with gene therapy for SMA11 May 2023 | By Catherine Eckford (European Pharmaceutical Review), Dr Sitra Tauscher-Wisniewski (Novartis Gene Therapies)Novartis Gene Therapies' Vice President for Clinical Development & Analytics shares what shaped the success of one of the few commercially-available gene therapies.
newsAntibody response varies for Big Pharma COVID vaccines9 May 2023 | By Catherine Eckford (European Pharmaceutical Review)Pfizer, Moderna and Johnson & Johnson COVID-19 vaccines produced varied neutralising antibody levels when assessed for short- and long-term response, says study.
